Nifty
Sensex
:
:
24968.40
81757.73
-143.05 (-0.57%)
-501.51 (-0.61%)

Pharmaceuticals & Drugs - Domestic

Rating :
63/99

BSE: 506943 | NSE: JBCHEPHARM

1654.10
18-Jul-2025
  • Open
  • High
  • Low
  • Previous Close
  •  1671.6
  •  1672.2
  •  1640.1
  •  1664.10
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  483356
  •  798616596.3
  •  2030
  •  1385.75

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 25,792.70
  • 39.10
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 25,677.05
  • 0.94%
  • 7.90

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 47.84%
  • 0.50%
  • 13.28%
  • FII
  • DII
  • Others
  • 18.3%
  • 18.03%
  • 2.05%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.27
  • 13.91
  • 7.55

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 17.47
  • 13.14
  • 8.19

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.13
  • 8.05
  • 17.19

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 28.26
  • 38.72
  • 44.81

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 5.34
  • 7.20
  • 8.08

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.37
  • 23.35
  • 26.98

Earnings Forecasts:

(Updated: 06-06-2025)
Description
2024
2025
2026
2027
Adj EPS
35.66
42.36
51.52
60.52
P/E Ratio
46.39
39.05
32.11
27.33
Revenue
3449
3918
4388
4909
EBITDA
892
1070
1198
1391
Net Income
553
660
815
947
ROA
14.6
16
17.8
18.9
P/B Ratio
8.89
7.50
6.40
5.44
ROE
20.45
20.75
21.48
21.55
FCFF
634
800
754
258
FCFF Yield
2.48
3.13
2.95
1.01
Net Debt
-83
-419
-1223
-991
BVPS
185.98
220.51
258.41
303.94

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Jun 24
Jun 23
Var%
Net Sales
949.48
861.73
10.18%
963.49
844.51
14.09%
1,000.62
881.74
13.48%
1,004.40
896.20
12.07%
Expenses
723.04
663.61
8.96%
708.98
621.39
14.10%
730.10
638.20
14.40%
724.03
664.09
9.03%
EBITDA
226.44
198.12
14.29%
254.51
223.12
14.07%
270.52
243.54
11.08%
280.37
232.11
20.79%
EBIDTM
23.85%
22.99%
26.42%
26.42%
27.04%
27.62%
27.91%
25.90%
Other Income
14.48
16.63
-12.93%
8.00
7.35
8.84%
9.95
7.66
29.90%
5.89
5.63
4.62%
Interest
1.45
9.41
-84.59%
2.58
12.49
-79.34%
2.06
10.37
-80.14%
5.64
12.06
-53.23%
Depreciation
46.44
40.74
13.99%
41.94
34.03
23.24%
41.88
32.17
30.18%
40.78
31.38
29.96%
PBT
193.03
164.60
17.27%
217.99
183.95
18.51%
236.53
208.66
13.36%
239.84
194.30
23.44%
Tax
47.34
38.44
23.15%
55.50
50.38
10.16%
61.96
58.07
6.70%
63.01
51.98
21.22%
PAT
145.69
126.16
15.48%
162.49
133.57
21.65%
174.57
150.59
15.92%
176.83
142.32
24.25%
PATM
15.34%
14.64%
16.86%
15.82%
17.45%
17.08%
17.61%
15.88%
EPS
9.36
8.13
15.13%
10.45
8.62
21.23%
11.24
9.72
15.64%
11.39
9.19
23.94%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
-
3,917.99
3,484.18
3,149.28
2,424.24
2,042.52
1,774.73
1,643.20
1,413.77
1,368.32
1,231.58
Net Sales Growth
-
12.45%
10.63%
29.91%
18.69%
15.09%
8.00%
16.23%
3.32%
11.10%
 
Cost Of Goods Sold
-
1,316.54
1,182.05
1,168.20
842.93
701.50
630.80
596.46
542.41
552.00
491.41
Gross Profit
-
2,601.44
2,302.13
1,981.08
1,581.31
1,341.02
1,143.93
1,046.74
871.35
816.32
740.17
GP Margin
-
66.40%
66.07%
62.91%
65.23%
65.66%
64.46%
63.70%
61.63%
59.66%
60.10%
Total Expenditure
-
2,886.87
2,591.70
2,453.53
1,881.63
1,486.35
1,397.15
1,337.36
1,214.64
1,135.93
1,025.55
Power & Fuel Cost
-
83.95
88.08
91.54
71.47
62.60
61.54
63.29
58.28
54.89
55.28
% Of Sales
-
2.14%
2.53%
2.91%
2.95%
3.06%
3.47%
3.85%
4.12%
4.01%
4.49%
Employee Cost
-
687.61
601.41
543.45
439.24
340.60
322.92
288.18
251.10
217.34
175.31
% Of Sales
-
17.55%
17.26%
17.26%
18.12%
16.68%
18.20%
17.54%
17.76%
15.88%
14.23%
Manufacturing Exp.
-
286.95
234.82
210.91
194.00
148.68
140.70
150.49
139.83
131.45
119.35
% Of Sales
-
7.32%
6.74%
6.70%
8.00%
7.28%
7.93%
9.16%
9.89%
9.61%
9.69%
General & Admin Exp.
-
127.18
119.69
110.09
100.46
56.35
48.14
52.97
53.96
42.26
34.82
% Of Sales
-
3.25%
3.44%
3.50%
4.14%
2.76%
2.71%
3.22%
3.82%
3.09%
2.83%
Selling & Distn. Exp.
-
288.65
268.40
233.96
161.80
113.22
116.95
113.59
87.44
78.27
72.72
% Of Sales
-
7.37%
7.70%
7.43%
6.67%
5.54%
6.59%
6.91%
6.18%
5.72%
5.90%
Miscellaneous Exp.
-
95.98
97.24
95.38
71.72
63.38
76.11
72.38
81.61
59.72
72.72
% Of Sales
-
2.45%
2.79%
3.03%
2.96%
3.10%
4.29%
4.40%
5.77%
4.36%
6.22%
EBITDA
-
1,031.12
892.48
695.75
542.61
556.17
377.58
305.84
199.13
232.39
206.03
EBITDA Margin
-
26.32%
25.62%
22.09%
22.38%
27.23%
21.28%
18.61%
14.09%
16.98%
16.73%
Other Income
-
39.04
41.67
9.94
40.07
116.62
50.90
41.44
55.29
50.16
56.65
Interest
-
11.73
44.33
36.05
5.12
7.24
3.26
4.65
3.49
5.37
10.65
Depreciation
-
171.04
138.32
114.41
72.66
68.67
66.32
55.64
56.97
47.22
41.22
PBT
-
887.39
751.51
555.23
504.90
596.89
358.89
286.99
193.95
229.94
210.82
Tax
-
227.81
198.88
145.23
118.86
148.36
76.50
93.02
55.23
45.55
49.58
Tax Rate
-
25.67%
26.46%
26.16%
23.54%
24.86%
21.93%
32.41%
28.48%
19.81%
23.52%
PAT
-
659.58
552.63
409.84
385.36
447.96
272.04
193.47
138.34
184.06
161.14
PAT before Minority Interest
-
659.58
552.63
410.01
386.04
448.52
272.39
193.97
138.72
184.40
161.24
Minority Interest
-
0.00
0.00
-0.17
-0.68
-0.56
-0.35
-0.50
-0.38
-0.34
-0.10
PAT Margin
-
16.83%
15.86%
13.01%
15.90%
21.93%
15.33%
11.77%
9.79%
13.45%
13.08%
PAT Growth
-
19.35%
34.84%
6.35%
-13.97%
64.67%
40.61%
39.85%
-24.84%
14.22%
 
EPS
-
42.36
35.49
26.32
24.75
28.77
17.47
12.43
8.89
11.82
10.35

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
3,433.32
2,923.33
2,480.35
2,134.12
1,809.72
1,435.49
1,480.12
1,441.56
1,363.67
1,183.84
Share Capital
15.57
15.52
15.48
15.46
15.46
15.46
16.05
16.71
16.96
16.96
Total Reserves
3,249.72
2,767.97
2,343.26
2,056.01
1,794.27
1,420.03
1,464.08
1,424.84
1,346.70
1,166.87
Non-Current Liabilities
443.23
465.96
992.03
475.34
72.47
62.72
64.84
45.66
26.98
31.02
Secured Loans
0.00
23.64
383.22
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
266.06
287.66
494.68
410.43
12.57
7.39
5.73
9.67
12.56
10.43
Current Liabilities
1,156.93
1,287.76
625.70
455.16
686.57
516.19
781.54
736.50
693.46
797.22
Trade Payables
410.72
356.31
238.65
224.48
186.92
167.97
117.37
110.39
98.98
90.85
Other Current Liabilities
137.33
435.75
240.33
81.31
89.82
102.67
93.10
119.75
122.15
138.73
Short Term Borrowings
13.80
15.34
28.02
26.32
32.64
29.49
25.80
29.29
48.86
193.02
Short Term Provisions
595.08
480.35
118.71
123.06
377.17
216.06
545.27
477.06
423.47
374.61
Total Liabilities
5,033.48
4,677.05
4,098.08
3,069.11
2,572.47
2,016.90
2,329.30
2,226.49
2,086.29
2,013.75
Net Block
1,968.19
2,004.40
1,901.01
1,276.99
633.65
651.26
620.93
639.50
679.44
440.22
Gross Block
2,964.52
2,835.23
2,607.77
1,876.20
1,182.55
1,177.43
1,084.83
1,053.76
1,038.55
753.75
Accumulated Depreciation
996.33
830.83
706.76
599.21
548.90
526.17
463.89
414.25
359.10
313.53
Non Current Assets
2,586.15
2,404.17
2,498.80
1,744.51
678.57
740.83
740.80
717.89
879.15
831.58
Capital Work in Progress
63.05
76.40
55.15
18.68
25.57
16.17
15.09
17.40
3.76
134.89
Non Current Investment
27.98
23.71
13.78
12.72
12.91
69.45
95.88
49.96
185.84
231.42
Long Term Loans & Adv.
275.94
293.64
514.35
435.07
5.62
3.59
8.31
10.15
9.43
22.63
Other Non Current Assets
250.98
6.03
14.51
1.04
0.82
0.36
0.59
0.88
0.67
2.43
Current Assets
2,447.33
2,272.87
1,599.29
1,324.61
1,893.89
1,276.08
1,588.51
1,508.59
1,207.14
1,182.16
Current Investments
317.11
364.65
192.18
0.00
664.97
333.81
360.65
383.77
224.96
247.28
Inventories
528.96
502.51
430.48
409.96
347.45
274.67
243.76
213.73
200.17
187.98
Sundry Debtors
815.38
686.92
575.80
555.69
389.02
345.43
308.22
300.73
265.97
272.64
Cash & Bank
129.45
95.54
78.81
58.53
30.85
30.95
36.80
29.92
13.39
12.90
Other Current Assets
656.44
33.09
44.91
57.43
461.61
291.22
639.08
580.44
502.66
461.34
Short Term Loans & Adv.
627.07
590.16
277.09
243.00
415.66
272.33
605.85
567.50
488.30
458.83
Net Current Assets
1,290.40
985.12
973.58
869.45
1,207.33
759.88
806.97
772.10
513.68
384.94
Total Assets
5,033.48
4,677.04
4,098.09
3,069.12
2,572.46
2,016.91
2,329.31
2,226.48
2,086.29
2,013.74

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
902.45
800.61
625.61
170.13
314.78
275.75
194.33
122.92
201.13
140.41
PBT
887.39
751.51
555.23
504.90
596.89
348.89
286.99
193.95
229.94
212.23
Adjustment
208.56
187.22
195.78
102.27
-46.17
7.95
23.72
16.91
13.11
-1.40
Changes in Working Capital
7.17
-5.64
-29.92
-302.42
-94.21
9.70
-51.47
-47.07
5.92
-16.96
Cash after chg. in Working capital
1,103.12
933.10
721.09
304.75
456.50
366.55
259.24
163.79
248.97
193.88
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-200.67
-132.49
-95.48
-134.62
-141.72
-90.80
-64.91
-40.87
-47.84
-53.47
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-295.90
-403.83
-961.79
2.32
-230.68
23.93
-27.67
-20.68
-45.31
-27.62
Net Fixed Assets
-104.26
-247.88
-761.82
-681.80
-12.39
-94.42
-29.82
-29.56
-152.86
-187.76
Net Investments
43.26
-192.30
-193.24
665.16
-274.62
53.26
-22.80
-22.92
67.89
-14.16
Others
-234.90
36.35
-6.73
18.96
56.33
65.09
24.95
31.80
39.66
174.30
Cash from Financing Activity
-579.67
-385.49
356.54
-138.39
-87.42
-306.05
-155.74
-59.52
-183.84
-99.62
Net Cash Inflow / Outflow
26.88
11.30
20.36
34.07
-3.31
-6.38
10.92
42.72
-28.02
13.17
Opening Cash & Equivalents
88.22
76.93
56.54
22.47
25.75
32.14
21.24
-21.47
6.54
-5.46
Closing Cash & Equivalent
115.09
88.22
76.93
56.54
22.47
25.75
32.14
21.24
-21.47
9.42

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
209.75
179.35
152.42
134.02
234.17
185.75
184.47
172.50
160.77
139.57
ROA
13.58%
12.60%
11.44%
13.69%
19.55%
12.53%
8.52%
6.43%
8.99%
9.21%
ROE
21.81%
21.49%
18.51%
19.89%
27.64%
18.69%
13.28%
9.89%
14.48%
14.80%
ROCE
26.73%
25.23%
22.79%
25.48%
36.53%
23.71%
19.59%
13.70%
16.87%
17.72%
Fixed Asset Turnover
1.40
1.32
1.46
1.63
1.73
1.57
1.54
1.35
1.53
1.82
Receivable days
67.54
63.93
63.16
69.29
65.62
67.22
67.63
73.15
71.84
79.28
Inventory Days
46.37
47.24
46.91
55.55
55.59
53.31
50.81
53.43
51.77
50.12
Payable days
106.33
91.86
72.35
89.07
92.33
38.74
32.21
33.66
32.86
32.45
Cash Conversion Cycle
7.58
19.31
37.72
35.77
28.88
81.79
86.23
92.93
90.75
96.95
Total Debt/Equity
0.00
0.13
0.23
0.01
0.02
0.02
0.02
0.02
0.04
0.16
Interest Cover
76.66
17.95
16.40
99.60
83.43
108.09
62.74
56.54
43.81
20.80

News Update:


  • J. B. Chemicals & Pharmaceuticals gets USFDA’s nod for Amitriptyline Hydrochloride Tablets
    25th Jun 2025, 09:19 AM

    Amitriptyline Hydrochloride Tablets is indicated for relief of symptoms of depression

    Read More
  • J.B. Chemicals & Pharmaceuticals secures USFDA’s approval for Bisoprolol Tablets
    21st Apr 2025, 14:21 PM

    Bisoprolol Tablets is indicated in the management of hypertension

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.